Mont-Saint-Guibert (Belgium), May 30, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.
Vestal Point Capital
On May 27, 2025, Nyxoah received a transparency notification from Vestal Point Capital following an acquisition or disposal of voting securities or voting rights. Based on the notification, Vestal Point Capital holds 1,809,843 voting rights, representing 4.84% of the total number of voting rights on May 21, 2025 (37,427,265).
The notification dated May 27, 2025 contains the following information:
A) Voting rights | Previous notification | After the transaction | |||
# of voting rights | # of voting rights | % of voting rights | |||
Holders of voting rights | Linked to securities | Not linked to the securities | Linked to securities | Not linked to the securities | |
Ryan Wilder | 0 | 0 | 0 | 0.00% | 0.00% |
Vestal Point Capital, LLC | 0 | 0 | 0 | 0.00% | 0.00% |
Vestal Point Capital, LP | 3,000,688 | 1,809,843 | 0 | 4.84% | 0.00% |
Subtotal | 3,000,688 | 1,809,843 | 4.84% | ||
TOTAL | 1,809,843 | 0 | 4.84% | 0.00% |
Contact:
Nyxoah
John Landry, CFO
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$6.51 |
Daily Change: | -0.06 -0.91 |
Daily Volume: | 121,422 |
Market Cap: | US$243.730M |
August 18, 2025 August 08, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load